BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
ORLADEYO™ (berotralstat) capsules ORLADEYO™ (berotralstat) capsules 150 mg —Significant and sustained reduction in HAE attacks— —Oral, once-daily prophylactic option enables...